These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 18241082)

  • 1. Adaptive dose finding based on t-statistic for dose-response trials.
    Ivanova A; Bolognese JA; Perevozskaya I
    Stat Med; 2008 May; 27(10):1581-92. PubMed ID: 18241082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Bayesian adaptive design for multi-dose, randomized, placebo-controlled phase I/II trials.
    Xie F; Ji Y; Tremmel L
    Contemp Clin Trials; 2012 Jul; 33(4):739-48. PubMed ID: 22426247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two-stage designs for Phase 2 dose-finding trials.
    Ivanova A; Xiao C; Tymofyeyev Y
    Stat Med; 2012 Oct; 31(24):2872-81. PubMed ID: 22865626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I/II seamless dose escalation/expansion with adaptive randomization scheme (SEARS).
    Pan H; Xie F; Liu P; Xia J; Ji Y
    Clin Trials; 2014 Feb; 11(1):49-59. PubMed ID: 24137041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An adaptive design for phase II non-oncology dose selection clinical trials.
    Su Z
    Clin Drug Investig; 2010; 30(6):397-403. PubMed ID: 20373828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved adaptive randomization strategies for a seamless Phase I/II dose-finding design.
    Yan D; Wages NA; Dressler EV
    J Biopharm Stat; 2019; 29(2):333-347. PubMed ID: 30451068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Add-Arm Design for Unimodal Response Curve with Unknown Mode.
    Chang M; Wang J
    J Biopharm Stat; 2015; 25(5):1039-64. PubMed ID: 25331003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose finding when the target dose is on a plateau of a dose-response curve: comparison of fully sequential designs.
    Ivanova A; Xiao C
    Pharm Stat; 2013; 12(5):309-14. PubMed ID: 23893900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Seamless Phase II/III combination study through response adaptive randomization.
    Wang L; Cui L
    J Biopharm Stat; 2007; 17(6):1177-87. PubMed ID: 18027224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal adaptive design in clinical drug development: a simulation example.
    Maloney A; Karlsson MO; Simonsson US
    J Clin Pharmacol; 2007 Oct; 47(10):1231-43. PubMed ID: 17906158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose finding with the sequential parallel comparison design.
    Wang JJ; Ivanova A
    J Biopharm Stat; 2014; 24(5):1091-101. PubMed ID: 24919070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Bayesian adaptive dose selection procedure with an overdispersed count endpoint.
    Pozzi L; Schmidli H; Gasparini M; Racine-Poon A
    Stat Med; 2013 Dec; 32(28):5008-27. PubMed ID: 24022748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Bayesian decision-theoretic sequential response-adaptive randomization design.
    Jiang F; Jack Lee J; Müller P
    Stat Med; 2013 May; 32(12):1975-94. PubMed ID: 23315678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SPIRIT: A seamless phase I/II randomized design for immunotherapy trials.
    Guo B; Li D; Yuan Y
    Pharm Stat; 2018 Sep; 17(5):527-540. PubMed ID: 29882388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using the partitioning principle to adaptively design dose-response studies.
    Ling X; Hsu J
    J Biopharm Stat; 2006; 16(5):733-43. PubMed ID: 17037268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of Bayesian hierarchical models for phase I/II clinical trials in oncology.
    Yada S; Hamada C
    Pharm Stat; 2017 Mar; 16(2):114-121. PubMed ID: 27892650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An adaptive, phase II, dose-finding clinical trial design to evaluate L-carnitine in the treatment of septic shock based on efficacy and predictive probability of subsequent phase III success.
    Lewis RJ; Viele K; Broglio K; Berry SM; Jones AE
    Crit Care Med; 2013 Jul; 41(7):1674-8. PubMed ID: 23514753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design considerations and analysis planning of a phase 2a proof of concept study in rheumatoid arthritis in the presence of possible non-monotonicity.
    Liu F; Walters SJ; Julious SA
    BMC Med Res Methodol; 2017 Oct; 17(1):149. PubMed ID: 28969588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Applications of Bayesian statistical methodology to clinical trial design: A case study of a phase 2 trial with an interim futility assessment in patients with knee osteoarthritis.
    Smith CL; Jin Y; Raddad E; McNearney TA; Ni X; Monteith D; Brown R; Deeg MA; Schnitzer T
    Pharm Stat; 2019 Jan; 18(1):39-53. PubMed ID: 30321909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adaptive designs for dose-finding in non-cancer phase II trials: influence of early unexpected outcomes.
    Resche-Rigon M; Zohar S; Chevret S
    Clin Trials; 2008; 5(6):595-606. PubMed ID: 19029208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.